Integra LifeSciences Launches Integra Mozaik(TM) Moldable Morsels for Bone Grafting Procedures

PLAINSBORO, N.J., Mar 10, 2010 (GlobeNewswire via COMTEX) — Integra LifeSciences Holdings Corporation(IART 42.00, -0.23, -0.54%) announced today the introduction of Integra Mozaik(TM) Moldable Morsels bone void filler, which will be available in four sizes. Integra Mozaik(TM) Moldable Morsels expands the successful Integra Mozaik(TM) product line by offering surgeons an innovative option for their bone grafting needs that provides enhanced composite grafting and optimized compression resistance.

Integra Mozaik(TM) Moldable Morsels is designed to fill bone voids or gaps in the skeletal system of the extremities, spine and pelvis. When used with bone marrow aspirate from the patient, Integra Mozaik(TM) Moldable Morsels may replace the need to harvest bone from the patient’s iliac crest, thus sparing the patient additional surgery and postoperative pain.

Integra Mozaik(TM) Moldable Morsels incorporates the same proprietary Type I collagen technology used in several of Integra’s innovative regenerative products, including DuraGen Plus(R) Dural Regeneration Matrix, NeuraGen(R) Nerve Guide, and INTEGRA(R) Dermal Regeneration Template. Integra Mozaik(TM) Moldable Morsels combines the collagen matrix with a highly pure form of beta-tricalcium phosphate to provide both compression resistance and a mineral source, two properties essential for bone healing. Integra Mozaik(TM) Moldable Morsels guide the regeneration of new bone across critical defect sites in which it has been implanted. New bone formation is initiated in the matrix surface when the graft is placed in direct apposition to living host bone. The matrix is resorbed and remodeled as new bone is formed.

“The introduction of Integra Mozaik(TM) Moldable Morsels marks another milestone in the continuing development of our collagen ceramic bone grafting platform, and provides surgeons with one of the most innovative options for bone grafting,” said Bill Weber, V.P. of Marketing, Product Development and Sales for Integra. “This introduction further establishes the Integra Mozaik(TM) platform as an industry leading choice for collagen ceramic bone graft substitutes.”

Degenerative disease of the spine becomes increasingly prevalent in the aging population. Patients who experience severe pain and do not respond to conservative therapies may require fusion of one or more vertebrae (spinal fusion). A spinal fusion is successful when the bones grow together biologically and form a solid mass. Bone grafts, and bone graft substitutes, such as the Integra Mozaik(TM) line of products, are frequently used by surgeons to aid and promote bone growth to achieve this desired biological fusion.

The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $1.5 billion. In 2009, an estimated 1,000,000 orthopedic procedures were performed in the United States, including over 500,000 spinal fusions. Additional applications are found in orthopedic trauma and reconstructive procedures.

The Integra OrthoBiologics distributor network sells Integra Mozaik(TM) Moldable Morsels in the United States. The Integra OrthoBiologics network currently distributes Accell(R), DynaGraft(R), and OrthoBlast(R) demineralized bone matrices, as well as the Integra Mozaik(TM) Osteoconductive Scaffold (Strip and Putty). This extensive product line allows the distributor network to provide a complete range of bone graft substitutes to orthopedic surgeons and neurosurgeons.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Integra’s products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information visitwww.integra-ls.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART – P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.